Dual-targeted and pH-sensitive Doxorubicin Prodrug-Microbubble Complex with Ultrasound for Tumor Treatment

Theranostics. 2017 Jan 5;7(2):452-465. doi: 10.7150/thno.16677. eCollection 2017.

Abstract

In this study, we investigated the potential of a dual-targeted pH-sensitive doxorubicin prodrug-microbubble complex (DPMC) in ultrasound (US)-assisted antitumor therapy. The doxorubicin prodrug (DP) consists of a succinylated-heparin carrier conjugated with doxorubicin (DOX) via hydrazone linkage and decorated with dual targeting ligands, folate and cRGD peptide. Combination of microbubble (MB) and DP, generated via avidin-biotin binding, promoted intracellular accumulation and improved therapeutic efficiency assisted by US cavitation and sonoporation. Aggregates of prepared DP were observed with an inhomogeneous size distribution (average diameters: 149.6±29.8 nm and 1036.2±38.8 nm, PDI: 1.0) while DPMC exhibited a uniform distribution (average diameter: 5.804±2.1 μm), facilitating its usage for drug delivery. Notably, upon US exposure, DPMC was disrupted and aggregated DP dispersed into homogeneous small-sized nanoparticles (average diameter: 128.6±42.3 nm, PDI: 0.21). DPMC could target to angiogenic endothelial cells in tumor region via αvβ3-mediated recognition and subsequently facilitate its specific binding to tumor cells mediated via recognition of folate receptor (FR) after US exposure. In vitro experiments showed higher tumor specificity and killing ability of DPMC with US than free DOX and DP for breast cancer MCF-7 cells. Furthermore, significant accumulation and specificity for tumor tissues of DPMC with US were detected using in vivo fluorescence and ultrasound molecular imaging, indicating its potential to integrate tumor imaging and therapy. In particular, through inducing apoptosis, inhibiting cell proliferation and antagonizing angiogenesis, DPMC with US produced higher tumor inhibition rates than DOX or DPMC without US in MCF-7 xenograft tumor-bearing mice while inducing no obvious body weight loss. Our strategy provides an effective platform for the delivery of large-sized or aggregated particles to tumor sites, thereby extending their therapeutic applications in vivo.

Keywords: Doxorubicin prodrug; Dual-targeted; Microbubble complex; Ultrasound.; pH-sensitive.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibiotics, Antineoplastic / administration & dosage*
  • Antibiotics, Antineoplastic / pharmacokinetics
  • Breast Neoplasms / diagnostic imaging
  • Breast Neoplasms / drug therapy*
  • Cell Survival / drug effects
  • Disease Models, Animal
  • Doxorubicin / administration & dosage*
  • Doxorubicin / pharmacokinetics
  • Drug Carriers / administration & dosage
  • Endocytosis
  • Endothelial Cells / metabolism
  • Heterografts
  • Humans
  • Hydrogen-Ion Concentration
  • MCF-7 Cells
  • Mice
  • Microbubbles*
  • Molecular Targeted Therapy / methods*
  • Nanoparticles / administration & dosage
  • Optical Imaging
  • Prodrugs / administration & dosage*
  • Prodrugs / pharmacokinetics
  • Sonication / methods*
  • Treatment Outcome
  • Ultrasonography

Substances

  • Antibiotics, Antineoplastic
  • Drug Carriers
  • Prodrugs
  • Doxorubicin